Immunovaccine (IMV)(IMMVF) Announces Regulatory Clearance for Phase 2 Clinical Trial Evaluating DPX-Survivac in Combination with Merck’s Checkpoint Inhibitor Pembrolizumab in DLBCL
Equities.com,
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage vaccine and immuno-oncology company, today announced that Health…